TY - JOUR
T1 - Management and treatment of glomerular diseases (part 1)
T2 - conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
AU - Conference Participants
AU - Floege, Jürgen
AU - Barbour, Sean J.
AU - Cattran, Daniel C.
AU - Hogan, Jonathan J.
AU - Nachman, Patrick H.
AU - Tang, Sydney C.W.
AU - Wetzels, Jack F.M.
AU - Cheung, Michael
AU - Wheeler, David C.
AU - Winkelmayer, Wolfgang C.
AU - Rovin, Brad H.
AU - Adler, Sharon G.
AU - Alpers, Charles E.
AU - Ayoub, Isabelle
AU - Bagga, Arvind
AU - Barratt, Jonathan
AU - Caster, Dawn J.
AU - Chan, Daniel T.M.
AU - Chang, Anthony
AU - Choo, Jason Chon Jun
AU - Cook, H. Terence
AU - Coppo, Rosanna
AU - Fervenza, Fernando C.
AU - Fogo, Agnes B.
AU - Fox, Jonathan G.
AU - Gibson, Keisha L.
AU - Glassock, Richard J.
AU - Harris, David
AU - Hodson, Elisabeth M.
AU - Hoxha, Elion
AU - Iseki, Kunitoshi
AU - Jennette, J. Charles
AU - Jha, Vivekanand
AU - Johnson, David W.
AU - Kaname, Shinya
AU - Katafuchi, Ritsuko
AU - Kitching, A. Richard
AU - Lafayette, Richard A.
AU - Li, Philip K.T.
AU - Liew, Adrian
AU - Lv, Jicheng
AU - Malvar, Ana
AU - Maruyama, Shoichi
AU - Mejía-Vilet, Juan Manuel
AU - Moeller, Marcus J.
AU - Mok, Chi Chiu
AU - Nester, Carla M.
AU - Noiri, Eisei
AU - O'Shaughnessy, Michelle M.
AU - Parikh, Samir M.
N1 - Funding Information:
JF declared having received consultancy fees from Amgen, Alnylam, Bayer, Boehringer Ingelheim, Calliditas, Inositec, Novo Nordisk, Omeros, and Vifor; speaker honoraria from Amgen and Vifor; and travel support from Boehringer Ingelheim. DCC declared having received consultancy fees from Alnylam, Calliditas, ChemoCentryx, Dimerix, Mallinckrodt, Novartis, and Rigel; and research support from Genentech and National Institute of Diabetes, Digestive, and Kidney Diseases. JJH declared having received consultancy fees from Aurinia, Dimerix, and Variant. PHN declared having received research support from Immune Tolerance Network. SCWT declared having received consultancy fees from AstraZeneca, Boehringer Ingelheim, and Sanofi. JFMW declared having received research support from Dutch Kidney Foundation and European Union FP7 programme (EUrenOmics); and future research support from Achillion and ChemoCentryx. DCW declared having received consultancy fees from Akebia, AstraZeneca, Amgen, Boehringer Ingelheim, GlaxoSmithKline, Janssen, and Vifor Fresenius; speaker honoraria from Amgen and Vifor Fresenius; and research support from AstraZeneca. WCW declared having received consultancy fees from Akebia, AMAG, Amgen, AstraZeneca, Bayer, Daichii-Sankyo, Relypsa, and ZS Pharma; speaker honoraria from FibroGen; and research support from National Institutes of Health. BHR declared having received consultancy fees from Alexion, Aurinia, Biogen, Biomarin, Bristol-Myers Squibb, ChemoCentryx, EMD Serono, Frazier Life Sciences, Genentech, Gilead, Lupus Foundation of America, Mallinckrodt, MedImmune, Novartis, Pharmalink, Ra Pharmaceuticals, Retrophin, and Rigel; and travel support from American Society of Nephrology, Aurinia, Biogen, Budapest Nephrology School, Childhood Arthritis and Rheumatology Research Alliance, ChemoCentryx, Congress on SLE (Australia), Central Society for Clinical and Translational Research-Midwestern American Federation for Medical Research, CureGN, European League Against Rheumatism Congress and Portuguese Congress, KDIGO, MENTOR (Multicenter Randomized Controlled Trial of Rituximab), Office of Minority Health Impact for Lupus, Pharmalink, Ra Pharmaceuticals, Retrophin, and UpToDate. All other authors declared no competing interests.
Funding Information:
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Achillion, Aurinia Pharmaceuticals, Calliditas Therapeutics, ChemoCentryx, Chugai, Expedition Therapeutics, Gilead, Goldfinch Bio, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Novartis, Omeros, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma.
Publisher Copyright:
© 2019 The Author(s)
PY - 2019/2
Y1 - 2019/2
N2 - The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline's publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.
AB - The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline's publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.
KW - IgA nephropathy
KW - KDIGO
KW - hypertension
KW - kidney biopsy
KW - membranous nephropathy
KW - proteinuria
UR - http://www.scopus.com/inward/record.url?scp=85059848558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059848558&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2018.10.018
DO - 10.1016/j.kint.2018.10.018
M3 - Article
C2 - 30665568
AN - SCOPUS:85059848558
SN - 0085-2538
VL - 95
SP - 268
EP - 280
JO - Kidney international
JF - Kidney international
IS - 2
ER -